Merck's new injectable cancer drug, Keytruda Qlex, promises to transform patient treatment with a quick administration time and flexible dosing, all while maintaining effectiveness. Available in late September, this shift is critical as the market braces for biosimilar competition.
GSK announces a groundbreaking $30 billion investment in the U.S. as President Trump visits the U.K. This commitment aims to enhance biopharma manufacturing and research, promising advancements in drug discovery and healthcare innovation.
AstraZeneca has unveiled an at-home delivery option for its FluMist nasal spray flu vaccine, allowing parents to vaccinate their children without leaving home. This groundbreaking move aims to boost vaccination rates amid declining flu shot coverage.
Health Secretary Robert F. Kennedy Jr.'s drastic funding cuts to mRNA vaccine research could stymie medical breakthroughs and push scientific talent away from the U.S., experts warn.
A groundbreaking study reveals that a blood test can identify Alzheimer's patients at risk of rapid decline. Researchers highlight the importance of insulin resistance in accelerating cognitive impairment, opening doors for timely interventions.
Starting late June, a groundbreaking blood test designed to diagnose Alzheimer’s disease will be available in the U.S., offering a faster and more cost-effective alternative to traditional methods. This innovation could revolutionize Alzheimer’s treatment and improve patient outcomes!
The FDA has approved the first blood test for Alzheimer's, allowing for earlier diagnosis and treatment with existing drugs. This groundbreaking development could significantly impact millions facing cognitive decline.
As organ shortages persist, scientists explore xenotransplantation — transplanting animal organs into humans. Discover the groundbreaking history and future potential of this life-saving innovation.
The FDA has approved a groundbreaking blood test, Lumipulse, that detects amyloid plaques linked to Alzheimer’s disease, offering a safer, more accessible diagnostic tool for millions.
The FDA has approved the Teal Wand, the first at-home alternative to Pap smears, offering a painless and convenient way for women to screen for cervical cancer. With the aim of increasing screening rates, this innovative device allows women to collect samples at home and mail them for lab testing.